
Pharmacally
Sjögren’s Disease
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Sjögren’s Disease
Clinical TrialsNovartis Reports Two-Year Ianalumab Results in Sjögren’s DiseaseNovartis presented Week 108 findings from the NEPTUNUS extension study, showing further reductions in systemic disease activity with monthly ianalumab in patients with Sjögren’s disease.Fact-Checked
Clinical TrialsAmgen Reports Phase 3 Success for Dazodalibep in Sjögren’s DiseaseAmgen’s Phase 3 OASIZ-301 trial showed that dazodalibep significantly reduced systemic disease activity in Sjögren’s disease at Week 48 with both four-weekly and 12-weekly dosing.Fact-Checked
Clinical Trialsargenx Halts Phase 3 UNITY Study of Efgartigimod After Futility Review in Sjögren’s Diseaseargenx will discontinue the Phase 3 UNITY study of subcutaneous efgartigimod in Sjögren’s disease after an interim futility review concluded the trial was unlikely to meet its primary…Fact-Checked
Clinical TrialsAmgen’s Dazodalibep Meets Phase 3 Endpoint in Sjögren’s DiseaseAmgen’s Phase 3 OASIZ 301 study found that dazodalibep significantly reduced systemic disease activity in adults with moderate-to-severe Sjögren’s disease, with improvements sustained through Week 48.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.